Canwell Biotech Ltd. has described tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer.
Suzhou Genhouse Bio Co. Ltd. has disclosed tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer, Noonan syndrome and Leopard syndrome.
Tyligand Bioscience Ltd. has prepared and tested tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer.
Researchers from China Pharmaceutical University reported the discovery and preclinical characterization of allosteric inhibitors of Src homology-2-containing protein tyrosine phosphatase 2 (SHP2) as potential new anticancer agents.
Shenzhen Genuine Biotech Co. Ltd. has disclosed tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) allosteric inhibitors reported to be useful for the treatment of cancer.
Jacobio Pharmaceuticals Group Co. Ltd. out-licensed rights for two lung cancer assets in China to Shanghai Allist Pharmaceuticals Co. Ltd. through a potential ¥900 million (US$126.4 million) deal. Beijing-headquartered Jacobio said Aug. 30 that it signed off development, regulatory and commercial milestone rights to both glecirasib, a KRAS G12C inhibitor first targeting non-small-cell lung cancer, and a SHP2 inhibitor called JAB-3312.
Jiangsu Vcare Pharmatech Co. Ltd. has disclosed tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer.
Researchers at CNCCS Scarl (Collezione Nazionale Dei Composti Chimici E Centro Screening) and IRBM SpA have disclosed tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP2) inhibitors reported to be useful for the treatment of cancer, Noonan and Leopard syndrome.
Despite GTPase KRAS being the most common mutated oncogene in human cancers, there is still an unmet medical need for treating KRAS G12C-mutated cancers.
Shouyao Holdings (Beijing) Co. Ltd. has patented tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer and Noonan syndrome.
